Head to head
BPC-157 against Wolverine blend
A single peptide against the blend built around it. Wolverine is usually 10 mg each of BPC-157 and what is sold as TB-500, and no study has tested the combination, so the blend cannot have more evidence than its parts and has one extra uncertainty about what the second component is.
Column A
BPC-157Body Protection Compound 157
A pentadecapeptide with a large animal literature on tendon, ligament, muscle and gut healing, and a small human record: two rectal-enema studies run in Croatia, three uncontrolled clinic reports, and a randomized Phase 2 injury trial now recruiting.
Column B
Wolverine blendWolverine (BPC-157 + TB-500)
Two gray-market healing peptides in one vial, usually 10 mg of each, sold for injury recovery. No study has ever tested the combination. BPC-157's systematic review found 36 studies of which 35 were preclinical, and what vendors sell as TB-500 is not thymosin beta 4 but a seven amino acid fragment of it.
Side by side, on the facts we can check
| Attribute | BPC-157 | Wolverine blend |
|---|---|---|
| Category | Healing & Recovery | Healing & Recovery |
| FDA status | Not FDA-approved. Removed from Category 2 (April 2026); PCAC voted 8 to 6, one abstention, to recommend for compounding (July 2026) against the FDA reviewers' recommendation; awaiting FDA action | Not approved, and the combination has never been evaluated. FDA staff reviewed BPC-157 for the July 2026 Pharmacy Compounding Advisory Committee meeting and found no adequate human data along with mislabelled products in the market. Neither component is an approved medicine anywhere. |
| Half-life | Under 30 minutes in plasma in a two-person pilot; the animal literature describes effects lasting hours to days. | Not defined for the blend, and the components differ. A systematic review reports BPC-157 as hepatically metabolised with a half-life under 30 minutes and renal clearance. |
| Molecular weight | 1,419.5 Da | A mixture. BPC-157 is about 1,419 Da. The Ac-LKKTETQ fragment identified in TB-500 is about 861 Da, well short of the roughly 4,960 Da of full-length thymosin beta 4. |
| Mechanism | In animal work BPC-157 promotes angiogenesis, interacts with the nitric oxide system, and raises growth hormone receptor expression and growth factor signaling in tendon fibroblasts. No receptor or molecular target has been identified, which FDA's 2026 evaluation gave as one reason it could not judge biological plausibility. Human mechanistic work is limited to the observation that the peptide was not detectable in plasma after rectal dosing, and to a two-person pilot consistent with a plasma half-life under 30 minutes, against effects that animal studies describe as lasting hours to days. | Assumed additive, and assumed is the operative word. BPC-157 is reported in preclinical models to raise growth hormone receptor expression and several pathways involved in cell growth and angiogenesis while reducing inflammatory cytokines. The thymosin beta 4 parent protein sequesters G-actin and promotes cell migration, and the Ac-LKKTETQ fragment that TB-500 actually contains sits within the actin-binding region. No paper describes what happens when the two are given together, whether their effects are additive, redundant or interfering, or whether the two peptides are stable in one vial. |
| Human studies cited | 5 | 1 |
| Legal status, US | Not approved; research use only | Not approved; research use only |
Frequently asked questions
What is the difference between BPC-157 and Wolverine blend?
BPC-157: A pentadecapeptide with a large animal literature on tendon, ligament, muscle and gut healing, and a small human record: two rectal-enema studies run in Croatia, three uncontrolled clinic reports, and a randomized Phase 2 injury trial now recruiting. Wolverine blend: Two gray-market healing peptides in one vial, usually 10 mg of each, sold for injury recovery. No study has ever tested the combination. BPC-157's systematic review found 36 studies of which 35 were preclinical, and what vendors sell as TB-500 is not thymosin beta 4 but a seven amino acid fragment of it.
Which has stronger research evidence, BPC-157 or Wolverine blend?
This database does not grade compounds. It counts what was run in people: 5 of the 12 studies cited on the BPC-157 profile were human work, against 1 of 8 for Wolverine blend. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are BPC-157 and Wolverine blend FDA-approved?
BPC-157: Not FDA-approved. Removed from Category 2 (April 2026); PCAC voted 8 to 6, one abstention, to recommend for compounding (July 2026) against the FDA reviewers' recommendation; awaiting FDA action. Wolverine blend: Not approved, and the combination has never been evaluated. FDA staff reviewed BPC-157 for the July 2026 Pharmacy Compounding Advisory Committee meeting and found no adequate human data along with mislabelled products in the market. Neither component is an approved medicine anywhere..
Related posts
Blog articles that cover BPC-157 or Wolverine blend, newest first.
- Healing & Recovery / Sep 8, 2026 / 9 minPeptides for Joint Pain: BPC-157, TB-500, Lorecivivint, Pentosan and Collagen Peptides, Evidence Tiered
- Healing & Recovery / Sep 8, 2026 / 8 minPeptides for Gut Health: BPC-157, KPV and Larazotide Ranked by Human Evidence
- Safety / Sep 8, 2026 / 9 minPeptide Side Effects by Class: What Is Documented, What Is Anecdotal
- Safety / Sep 8, 2026 / 8 minHow to Read a Peptide Certificate of Analysis: HPLC Purity, Mass Spec Identity, Endotoxin, and Janoshik Verification
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.